Adap­ti­m­mune gets a par­tial hold on piv­otal T-cell study, but it seems OK to breathe now

The FDA is tap­ping the brakes on one of Adap­ti­m­mune T-cell stud­ies, look­ing for some clar­i­fi­ca­tions be­fore it gives the green light to start test­ing NY-ESO SPEAR T-cell ther­a­py in myx­oid round cell li­posar­co­ma.

No doubt there were a few skipped heart beats among in­vestors, but the UK biotech $ADAP hur­ried on to ex­plain that reg­u­la­tors are sim­ply look­ing to get a few an­swers for a reg­is­tra­tion tri­al that has yet to start re­cruit­ing pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.